SVRA

Savara, Inc.

NASDAQ

Add Alert

SVRA

Savara, Inc.

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Monksdream PremiumMember

03/29/24 12:59 PM

Post #288

SVRA under $5

TrendTrade2016 PremiumMember

12/11/23 3:04 PM

Post #287

SVRE fresh nazy with volume

glenn1919

08/27/23 12:19 PM

Post #286

SVRA.......................https://stockcharts.com/h-sc/ui?s=SVRAp=W&b=5&g=0&id=p86431144783

Monksdream PremiumMember

08/12/23 12:25 PM

Post #285

SVRA new 52 week high

glenn1919

06/10/23 9:37 AM

Post #284

SVRA................................https://stockcharts.com/h-sc/ui?s=SVRA&p=W&b=5&g=0&id=p86431144783

glenn1919

06/03/23 4:32 PM

Post #283

Re: #282: @glenn1919 - SVRA.................................https://stockcharts.com/h-sc/ui?s=SVRAp=W&b

SVRA...................https://stockcharts.com/h-sc/ui?s=SVRA&p=W&b=5&g=0&id=p86431144783

glenn1919

05/27/23 1:29 PM

Post #282

Re: #281: @glenn1919 - SVRA.................................https://stockcharts.com/h-sc/ui?s=SVRA&p=W&

SVRA.................................https://stockcharts.com/h-sc/ui?s=SVRAp=W&b=5&g=0&id=p86431144783

glenn1919

05/20/23 8:22 AM

Post #281

SVRA.................................https://stockcharts.com/h-sc/ui?s=SVRA&p=W&b=5&g=0&id=p86431144783

AKAPAK

01/26/23 12:46 PM

Post #280

Re: #251: @Biobonic - Their latest presentation is worth a listen http://wsw.com/webcast/evercore4/svra/index.aspx[/

Impala must be doing better ... hod $2.82 been making nice moves during last few days!

AKAPAK

01/25/23 1:35 PM

Post #279

Re: #278: @Mrfairfield - Finally done dumping on the new financials.

Wake up call to the board $2.47

Mrfairfield Free

05/14/21 9:57 AM

Post #278

Finally done dumping on the new financials. Looks like consolidation and ??????

20stockman20 Free

03/23/21 10:32 AM

Post #277

Looking for comments,
What some see as a dump, others see as an opportunity.
What say you?

Roadtojourney Free

03/22/21 3:23 PM

Post #276

Wow looks like dump is still on imo

20stockman20 Free

03/20/21 1:45 PM

Post #275

Check out what BARCHART has to say about SVRA

Barchart Technical Opinion
STRONG BUY
The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

20stockman20 Free

03/18/21 11:11 AM

Post #274

Re: #273: @lecorb - Savara Inc Stock may give you a sharp

jumped in, looks good to me

lecorb

03/18/21 1:05 AM

Post #273

Re: #272: @Klinsmann - Not really, had 120 million volume yesterday

Savara Inc Stock may give you a sharp bounce - svra stock

Last Ratings
3/16/2021 Piper Sandler Initiated Coverage Overweight $7.00 High
3/15/2021 Oppenheimer Initiated Coverage Outperform $4.00 High

Klinsmann

03/17/21 10:40 AM

Post #272

Re: #271: @ronjon41 - The volume today should say it all, surpassed

Not really, had 120 million volume yesterday
But volume is far about average and chart is building!
Many big institutional investors, plus company insiders holding big positions.

ronjon41

03/17/21 10:36 AM

Post #271

Re: #267: @Klinsmann - Jep, 100% agree. It traded volume of a

The volume today should say it all, surpassed yesterdays volume in the first 30 minutes.

maximumgriff Free

03/17/21 8:52 AM

Post #270

Re: #268: @trendzone - Corrupt MM's manipulation brought it down from the

Looks like they still at it

Jess070283 Free

03/17/21 8:27 AM

Post #269

This is one you need for long term. Just warming up. My price target is $5-10!

trendzone

03/17/21 7:31 AM

Post #268

Re: #267: @Klinsmann - Jep, 100% agree. It traded volume of a

Corrupt MM's manipulation brought it down from the highs yesterday's.

Klinsmann

03/17/21 3:33 AM

Post #267

Re: #266: @maximumgriff - Closed a massive 130 mill Offering! Check out

Jep, 100% agree. It traded volume of a whole year on one day while insiders have been buying. For reason imo

maximumgriff Free

03/16/21 8:41 PM

Post #266

Re: #257: @BoilerRoom - What’s the offering price?

Closed a massive 130 mill Offering! Check out the AH filings! This will run soon!!

ClayTrader Free

03/16/21 4:07 PM

Post #264

* * $SVRA Video Chart 03-16-2021 * *

Link to Video - click here to watch the technical chart video

DMOST

01/06/20 9:37 PM

Post #263

In the money Jan. 6: Drug, burger makers report multimillion-dollar fundings

..................................

• Savara Inc. has raised about $26.8 million as it develops drugs to treat rare lung diseases. The Austin-based pharmaceutical company announced Dec. 20 it intended to sell more than 9.5 million shares of common stock and pre-funded warrants to buy more than 5.7 million shares in a private placement with "institutional investors," which would generate the $26.8 million, although Savara (Nasdaq: SVRA) still needs to deduct placement agent fees and other offering expenses. The company filed securities paperwork Jan. 2 indicating it had raised the $26.8 million from 18 investors. Savara said Dec. 20 it has also agreed to sell warrants that could allow investors to buy more than 32.5 million additional shares of common stock. The warrants can be exercised by investors two years after the close of this private placement or 30 days after Savara achieves a certain clinical milestone, whichever is earlier. That sale could raise gross proceeds of $48.2 million, according to the company, before deducting expenses and fees. Bain Capital Life Sciences led the placement and Ricky Sun of Bain Capital has joined Savara's board of directors. Investors in the private placement included EcoR1 Capital LLC and Logos Capital. Founded in 2008, Savara is led by CEO Rob Neville and develops drugs for orphan lung diseases such as autoimmune pulmonary alveolar proteinosis and nontuberculous mycobacteria.
https://www.bizjournals.com/austin/news/2020/01/06/in-the-money-jan-6-drug-burger-makers-report.html?ana=yahoo&yptr=yahoo

GO SVRA

"PEACE"

DMOST

01/06/20 9:32 PM

Post #262

DMOST....."In Like Flint", look towards a huge pay day down the road, in a relatively short time frame.

Are Options Traders Betting on a Big Move in Savara (SVRA) Stock?

Investors in Savara Inc. SVRA need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2020 $5.00 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?

Clearly, options traders are pricing in a big move for Savara shares, but what is the fundamental picture for the company? Currently, Savara is a Zacks Rank #3 (Hold) in the Medical - Drugs industry that ranks in the Top 23% of our Zacks Industry Rank. Over the last 30 days, one analyst has increased the earnings estimate for the current quarter, while none have dropped their estimates. The net effect has narrowed our Zacks Consensus Estimate for the current quarter from a loss of 52 cents per share to a loss of 49 cents in that period.

Given the way analysts feel about Savara right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
https://finance.yahoo.com/news/options-traders-betting-big-move-143002217.html

GO SVRA

"PEACE"

ClayTrader Free

01/02/20 5:10 PM

Post #261

* * $SVRA Video Chart 01-02-2020 * *

Link to Video - click here to watch the technical chart video

ClayTrader Free

12/31/19 5:05 PM

Post #260

* * $SVRA Video Chart 12-31-2019 * *

Link to Video - click here to watch the technical chart video

chrispy2468 Free

12/31/19 2:21 PM

Post #259

So. We buying calls or puts? 5 strikes.

boston127

12/31/19 10:41 AM

Post #258

Re: #254: @Hercules1 - I did the same damn thing:

We never lose taking profits.

I'm waiting for the right moment to get back in. It will probably not be today. I also have 2 other stocks on my radar that I have been following, and investing in, for awhile. US*W*S and AU**XX*F

BoilerRoom Free

12/31/19 9:08 AM

Post #257

What’s the offering price?

alchemytrader Free

12/31/19 7:58 AM

Post #256

Re: #255: @BoilerRoom - Looks like run is over here. Needs consolidate

You were alerted at 2.30 multiple times bud.

BoilerRoom Free

12/31/19 7:54 AM

Post #255

Looks like run is over here. Needs consolidate

Hercules1

12/30/19 11:29 PM

Post #254

Re: #252: @boston127 - I got it - sold too soon.

I did the same damn thing:

I sold too soon for a decent profit but should have held on for a day or two.

williamssc Free

12/30/19 10:40 PM

Post #253

$$Nice move up today. Congrats.
5.7400 +0.83 (16.90%)
After hours: 7:59PM EST

boston127

12/30/19 10:29 PM

Post #252

Re: #246: @Biobonic - Go to the presentations on SVRA website

I got it - sold too soon.

Was so glad to make a buck, sold way too soon. I will get back in tomorrow after seeing the after hours action and the Bain Capital's 9.9% stake.

Biobonic

12/30/19 6:11 PM

Post #251

Their latest presentation is worth a listen Savara

An understanding is that the Impala trial would have passed if not for a small group of 4 in the placebo group who use oxygen. Their use of oxygen is necessary, and they were allowed to use oxygen during the actual 6 minute walk. The rate of oxygen they used during the walk increased due to the exertion necessary, this raised the placebo groups score.

Would appreciate any feedback...

north40000 PremiumMember

12/30/19 5:51 PM

Post #250

http://ih.advfn.com/stock-market/NASDAQ/savara-SVRA/stock-news/81434794/current-report-filing-8-k

http://ih.advfn.com/stock-market/NASDAQ/savara-SVRA/stock-news/81438175/statement-of-beneficial-ownership-sc-13d

http://ih.advfn.com/stock-market/NASDAQ/savara-SVRA/stock-news/81434542/savara-granted-breakthrough-therapy-designation-fo

"....The Molgradex Breakthrough Therapy designation is based on data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex for the treatment of aPAP. Data from the study was recently presented in an oral session at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain.

“We are pleased that the FDA recognized Molgradex as a breakthrough therapy for the treatment of aPAP, a debilitating rare lung disease with no approved pharmacologic treatment options,” said Rob Neville, Chief Executive Officer, Savara. “We believe this designation reflects the significance of Molgradex as an investigational product that, based on the IMPALA study, has been demonstrated to improve patient outcomes. Breakthrough designation is designed to provide increased collaboration and more frequent dialogue with the FDA and is an important milestone as we work to determine the best path forward for this product.”

About Savara

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)....."

Rocketred

12/30/19 5:30 PM

Post #248

over 6 buks now

davidsson10 Free

12/30/19 5:15 PM

Post #247

Re: #233: @davidsson10 - Well, the ol' Balls O' Steel deliver another

So far this evening, the $3.50 area is proving to have been a prescient reload point for Round Two. Another double waiting in the wings? We'll know soon enough.....